Renal clearance in drug discovery and development: Molecular descriptors, drug transporters and disease state

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 8, 2010, Pages 939-952

  Feng, Bo ^a   LaPerle, Jennnifer L ^a   Chang, George ^a   Varma, Manthena V ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

In silico models; Physicochemical properties; Renal clearance; Renal insufficiency; Transporters

Indexed keywords

ADEFOVIR; ANTINEOPLASTIC AGENT; CEFALORIDINE; CEPHALOSPORIN; CIDOFOVIR; CIMETIDINE; DIDANOSINE; ESTRONE SULFATE; METFORMIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; NONSTEROID ANTIINFLAMMATORY AGENT; OCHRATOXIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PRAVASTATIN; PROBENECID; PROCAINAMIDE; RANITIDINE; SITAGLIPTIN; TENOFOVIR; TETRYLAMMONIUM; UNINDEXED DRUG; VARENICLINE; DRUG;

COMPUTER MODEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG TRANSPORT; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; LIPOPHILICITY; MEMBRANE PERMEABILITY; NEPHROTOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; URINARY EXCRETION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG DEVELOPMENT; DRUG INTERACTION; DRUG SCREENING; KIDNEY; METABOLISM; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; KIDNEY; PHARMACEUTICAL PREPARATIONS;

EID: 77954846109     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.482930     Document Type: Review

References (70)

1. Hosea NA, Collard WT, Cole S, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009;49:513-533
2. Wang J, Urban L, Bojanic D. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin Drug Metab Toxicol 2007;3:641-665
3. Yengi LG, Leung L, Kao J. The evolving role of drug metabolism in drug discovery and development. Pharm Res 2007;24:842-858
4. Beaumont K, Smith DA. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr Opin Drug Discov Devel 2009;12:61-71
5. Varma MV, Feng B, Obach RS, et al. Physicochemical determinants of human renal clearance. J Med Chem 2009;52:4844-4852
6. Bonate PL, Reith K, Weir S. Drug interactions at the renal level. Implications for drug development. Clin Pharmacokinet 1998;34:375-404
7. Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ. Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet 2003;42:1193-1211
8. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65:757-773
9. Lave T, Chapman K, Goldsmith P, Rowland M. Human clearance prediction: shifting the paradigm. Expert Opin Drug Metab Toxicol 2009;5:1039-1048
10. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009;157:907-921
11. Kusuhara H, Sugiyama Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 2009;24:37-52
12. Sahi J. Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates. Expert Opin Drug Metab Toxicol 2005;1:409-427
13. Xia CQ, Milton MN, Gan LS. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 2007;8:341-363
14. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-277
15. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005;45:689-723
16. Doddareddy MR, Cho YS, Koh HY, et al. In silico renal clearance model using classical Volsurf approach. J Chem Inf Model 2006;46:1312-1320
17. Fagerholm U. Prediction of human pharmacokinetics - renal metabolic and excretion clearance. J Pharm Pharmacol 2007;59:1463-1471
18. Sun H, Lynda Frassetto, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006;109:1-11
19. Jappar D, Hu Y, Keep RF, Smith DE. Transport mechanisms of carnosine in SKPT cells: contribution of apical and basolateral membrane transporters. Pharm Res 2009;26:172-181
20. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 2001;1:277-351
21. Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615-2623
22. Bednarczyk D, Ekins S, Wikel JH, Wright SH. Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol 2003;63:489-498
23. Ullrich KJ. Renal transporters for organic anions and organic cations. Structural requirements for substrates. J Membr Biol 1997;158:95-107
24. Ahlin G, Karlsson J, Pedersen JM, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem 2008;51:5932-5942
25. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001;31:469-497
26. Inotsume N, Nishimura M, Nakano M, et al. The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J Clin Pharmacol 1990;30:50-56
27. Bendayan R, Sullivan JT, Shaw C, et al. Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol 1990;38:165-169
28. Kirch W, Rose I, Demers HG, et al. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 1987;13:110-117
29. Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987;23:545-551
30. Takeda M, Babu E, Narikawa S, Endou H. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 2002;438:137-142 (Pubitemid 34241501)
31. Manga N DJ, Rowe PH, Cromin MTD. A hierarchical QSAR model for urinary excretion of drugs in humans as a predictive tool for biotransformation. QSAR Comb Sci 2003;22:263-273
32. In: Hardman JG, Gilman AG, Limbird LE, editors, Goodman and Gilman's The Pharmacological Basis Of Therapeutics. McGraw-Hill, New York, USA; 1996
33. Cruciani G PM, Guba W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 2000;11:S29-39
34. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215-236
35. Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000;58:944-958
36. van Montfoort JE, Hagenbuch B, Groothuis GM, et al. Drug uptake systems in liver and kidney. Curr Drug Metab 2003;4:185-211
37. Koepsell H, Gorboulev V, Arndt P. Molecular pharmacology of organic cation transporters in kidney. J Membr Biol 1999;167:103-117
38. Cha SH, Sekine T, Fukushima JI, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 2001;59:1277-1286 (Pubitemid 32385197)
39. Lecureur V, Sun D, Hargrove P, et al. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 2000;57(1):24-35
40. Yamazaki M, Neway WE, Ohe T, et al. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol 2001;296(3):723-735
41. Masuda S, Terada T, Yonezawa A, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006;17:2127-2135
42. Otsuka M, Matsumoto T, Morimoto R, et al. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005;102:17923-17928
43. Tanihara Y, Masuda S, Sato T, et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochem Pharmacol 2007;74:359-371
44. Brown G. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet 1993;24:289-300
45. Bourke RS, Chheda G, Bremer A, et al. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res 1975;35:110-116
46. Masereeuw R, Russel FG. Mechanisms and clinical implications of renal drug excretion. Drug Metab Rev 2001;33:299-351
47. Sirtori CR FG, Galli-Kienle M, Cighetti G, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-693
48. Takeda M, Tojo A, Sekine T, et al. Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. Kidney Int 1999;56:2128-2136
49. Uwai Y, Ida H, Tsuji Y, et al. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 2007;24:811-815
50. Gekle M, Silbernagl S. The role of the proximal tubule in ochratoxin A nephrotoxicity in vivo: toxodynamic and toxokinetic aspects. Renal Physiol Biochem 1994;17:40-49
51. Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-886
52. Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007;74:477-487
53. Feng B, Obach RS, Burstein AH, et al. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther 2008;83:567-576
54. USRDS. 2009 Atlas of CKD and ESRD. United States Renal Data System; 2009
55. Cheng Q, Aleksunes LM, Manautou JE, et al. Drug-metabolizing enzymes and transporter expression in a mouse model of diabetes and obesity. Mol Pharm 2008;5:77-91
56. Ji L, Masuda S, Saito H, Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int 2002;62:514-524
57. Nowicki MT, Aleksunes LM, Sawant SP, et al. Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab Lett 2008;2:11-17
58. Laouari D, Yang R, Veau C, et al. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol Renal Physiol 2001;280:F636-45
59. Sakurai Y, Motohashi H, Ueo H, et al. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res 2004;21:61-67
60. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and disposition. Semin Dial 2003;16:45-50
61. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008;4:1065-1074
62. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83:898-903
63. Zhang Y, Zhang L, Abraham S, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 2009;85:305-311
64. Bianchetti G, Graziani G, Brancaccio D, et al. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1976;1:373-384
65. Giacomini KM, Gibson TP, Levy G. Plasma protein binding of d-propoxyphene in normal subjects and anephric patients. J Clin Pharmacol 1978;18:106-109
66. Kanfer A, Stamatakis G, Torlotin JC, et al. Changes in erythromycin pharmacokinetics induced by renal failure. Clin Nephrol 1987;27:147-150
67. De Martin S, Orlando R, Bertoli M, et al. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clin Pharmacol Ther 2006;80:597-606
68. Singlas E, Pioger JC, Taburet AM, et al. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther 1989;46:190-197
69. Kim YG, Shin JG, Shin SG, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther 1993;54:612-620
70. Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18:4872-4875